The company's technology center was established in December 2019, positioning itself to be an integrated technology research and development center for new drug research and development and production services. At present, the center mainly relies on the technical research and development team of the Jiangsu parent company to carry out in-depth development and production services of new anti-tumor and anti-viral drugs. Under the leadership of the National Thousand Talents Dr. Wang, the company has gradually established long-term and stable cooperative relations with large American pharmaceutical companies. The scope of services covers the research and synthesis of pharmaceutical intermediates and pesticide intermediates; the research and development and production of chemical drugs.

At the initial stage of its establishment, the enterprise technology center has been equipped with corresponding R&D and analysis equipment. Among them, there are small-scale research laboratories, pilot-scale synthesis laboratories, high-efficiency purification laboratories, and analytical laboratories. The analytical laboratory is equipped with advanced analytical equipment, Agilent liquid chromatography, Agilent gas chromatography, Waters UPLC and other equipment.

Based on the mission of taking research as the first and customer-centric, the Technology Center will help customers improve R&D efficiency through cost-effective and efficient R&D services and devote themselves to the development of more innovative drug projects under research.